Medical imaging software developer Mirada Medical has signed an agreement with clinical trial support firm ABX-CRO that will allow the company to use Mirada's multimodality imaging applications for clinical trials in oncology and the neurosciences.
Mirada's imaging applications support unlimited patient time points for follow-up assessment of CT, MR, PET, or SPECT studies, or any hybrid combination, according to Mirada.
ABX-CRO provides development services for imaging biomarkers and offers PET and SPECT imaging for therapy trials.
